Amgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug

Amgen reported Q1 adjusted EPS of $5.15, ahead of the $4.76 consensus, on revenue of $8.6 billion, in line with estimates and up 6% year over year. Management raised full-year 2026 guidance to $21.70-$23.10 for adjusted EPS and $37.1 billion-$38.5 billion for revenue, while MariTide Phase 3 development continues. Offsetting the upbeat results, FDA scrutiny of Tavneos and weaker Prolia sales, which fell 34% to $727 million, highlight regulatory and competitive risks.

Analysis

AMGN is showing a classic late-cycle franchise transition: mature immunology/bone assets are becoming a drag, while higher-quality cardiovascular and obesity optionality is starting to re-rate the stock. The key second-order effect is that Repatha strength can partially offset Prolia erosion, but the mix shift matters more than the headline revenue beat because the market will pay for durable, patent-protected growth, not flat aggregate sales masked by price discipline.

The bigger strategic signal is MariTide. If management can credibly take a differentiated GLP-1 into broad Phase 3 execution, AMGN moves from being a portfolio-defense story to a platform story, which typically expands the multiple before any data readout. That said, the obesity space is increasingly a capital-efficiency contest: investors will discount anything that looks like follow-on differentiation without clear superiority on tolerability, dosing convenience, or cardiometabolic outcomes, so the stock may struggle to sustain a rerate until protocol details and early safety de-risk the path.

The regulatory overhang on Tavneos is less about the near-term dollars and more about precedent. A label or approval challenge increases the probability that commercial teams spend more time on legal/regulatory defense than on expansion, and it raises the discount rate on the broader pipeline if the market starts to view execution as less clean. The most important reversal catalyst over the next 1-3 months is whether management can contain that issue to a narrow label amendment rather than a broader trust problem with the FDA.

Contrarian view: the market may be underestimating how much of AMGN’s value is now driven by portfolio resilience, not any single product. If Prolia declines are slower than expected and Repatha continues compounding, the earnings base becomes sturdier exactly as MariTide becomes investable optionality. In that setup, the stock can work even without immediate obesity enthusiasm, but the upside is likely to be released in stages rather than in one sharp rerating.

Key Decisions for Investors

• Go long AMGN into the next 4-8 weeks on weakness, targeting a modest rerating driven by Repatha durability and MariTide optionality; use a tight stop if Tavneos headlines broaden beyond label language.
• Buy AMGN Jan-2027 calls or call spreads to express the MariTide optionality with limited downside; the thesis works if the market begins capitalizing Phase 3 breadth before efficacy data.
• Pair trade: long AMGN / short a higher-multiple obesity platform name with less diversified earnings, to isolate relative value in pipeline optionality versus current cash flow support.
• If Tavneos regulatory pressure escalates, hedge AMGN with short-dated puts around the next FDA communication window; this is a days-to-weeks catalyst, not a structural thesis breaker unless enforcement expands.